B Cell News and Research

RSS

LLS awards two new grants through prestigious Marshall A. Lichtman SCOR research initiative

The Leukemia & Lymphoma Society today announced it has awarded two new grants through its prestigious Marshall A. Lichtman Specialized Center of Research research initiative, bringing the program's total funding to $210.5 million since its inception in 2000.

13 Jul 2010

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract, SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia.

13 Jul 2010

Examination of cellular construction of motion detector in brain of fly

What would be the point of holding a soccer world championship if we couldn't distinguish the ball from its background? Simply unthinkable! But then again, wouldn't it be fantastic if your favourite team's striker could see the movements of the ball in slow motion! Unfortunately, this advantage only belongs to flies.

13 Jul 2010

Amorfix Life Sciences uses A(4) test to detect accumulation of Abeta in mouse models of AD

Amorfix Life Sciences, a company focused on treatments and diagnostics for misfolded protein diseases including Alzheimer's disease, has used its A(4) test to compare the rate of accumulation of aggregated Abeta in the brain tissue of various mouse models of AD. Amorfix presented this new data at the International Conference on Alzheimer's Disease this week.

13 Jul 2010

New study on impact of bortezomib on mantle cell lymphoma

A new study by researchers from the John Theurer Cancer Center at Hackensack University Medical Center sheds light on how bortezomib (VELCADE-), the first in a new class of cancer drugs known as proteasome inhibitors, works in mantle cell lymphoma. The study also provides preliminary evidence for which patients might benefit most from bortezomib.

13 Jul 2010

Stem cell transplantation from healthy donor helps cure aggressive form of CLL

The transplantation of stem cells from a healthy donor (allogeneic) offers the chance of cure for patients with an aggressive form of chronic lymphocytic leukemia (CLL), irrespective of genetic prognostic factors and the prior course of the disease. The German CLL Study Group proved this in a multicentric clinical phase II study led by Professor Dr. Peter Dreger, senior consultant and head of the division of stem cell transplantation at the Department of Internal Medicine V at Heidelberg University Hospital.

13 Jul 2010

GWAS suggests genetic variant with increased oncogene expression for cancer study

The study, published July 13th in Genome Research, showcases a new protocol for studying the activity of cancer-risk variants suggested by GWAS studies. The results also underscore the dramatic consequences of small genetic changes even in the vast stretches of DNA, known as "gene deserts," that do not code for proteins.

13 Jul 2010

Sheffield Bio-Science honored with 2010 Lilly Global Supplier Award

Sheffield Bio-Science, a leading global pharmaceutical supplier of superior quality cell nutrition and excipient products for the biotech and pharmaceutical markets, has been awarded the distinguished 2010 Lilly Global Supplier Award.

13 Jul 2010

New research shows head size helps measure brain reserve, brain growth

New research shows that people with Alzheimer's disease who have large heads have better memory and thinking skills than those with the disease who have smaller heads, even when they have the same amount of brain cell death due to the disease. The research is published in the July 13, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

13 Jul 2010

HighRes Biosolutions to provide high-throughput screening automation to Rigel

HighRes Biosolutions, the leader in laboratory automation solutions for life science, announced today that it will be providing high-throughput screening automation to Rigel Pharmaceuticals, a South San Francisco, California-based clinical-stage drug development company.

13 Jul 2010

Researchers identify genetic variant associated with increased risk of AAA

Geisinger researchers are part of an international team that has identified a genetic variant more common in individuals with abdominal aortic aneurysms. This is one of the largest studies ever into the genetics of AAA. The results of the work will appear in this week's online edition of Nature Genetics.

13 Jul 2010

Larger heads may protect against Alzheimer’s disease: Study

A larger head may be offer natural protection against dementia and Alzheimer’s disease say researchers in a study conducted on 270 patients and published in the journal Neurology.

13 Jul 2010

Vivakor expands distribution channels of VivaThermic vials

Vivakor, Inc. announced that it has expanded United States distribution of its VivaThermic vials. A listing of Authorized Distributors of VivaThermic vials is available at www.vivathermic.com/distributors.

13 Jul 2010

Scientists receive $1.6M in new funding to advance healthcare research

University of Montreal scientists have received $1.6 in new funding to advance healthcare research over the next three years, as part of a Government of Canada announcement to support 31 research projects at 12 universities across the nation. Some $13 million in funding, from the Collaborative Health Research Projects program, will be awarded over three years to foster collaborations between scientists from the natural, engineering and health sciences.

13 Jul 2010

Study explores direct role of FTO gene on Alzheimer's and dementia risk in old age

A gene known as FTO, which appears to be correlated with obesity in humans, may also increase risk of Alzheimer's disease and dementia, according to new research presented today at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 in Honolulu, HI. And when a person has certain variants of both FTO and a recognized Alzheimer's risk gene known as APOE, the risk of Alzheimer's could be doubled.

13 Jul 2010

Westbury Hospital to implement Prognosis ChartAccess Comprehensive EMR

Westbury Hospital is implementing an electronic medical records system from Prognosis Health Information Systems – a move that is putting the new 137-bed acute care hospital on the fast track toward meeting meaningful use requirements and qualifying for incentive funds associated with the American Recovery and Reinvestment Act (ARRA).

12 Jul 2010

Accuri Cytometers announces completion of $6 million Series E preferred stock financing

Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. The financing included current investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse.

12 Jul 2010

Scientists discover way to enhance nerve regeneration in peripheral nervous system

Faculty of Medicine scientists have discovered a way to enhance nerve regeneration in the peripheral nervous system. This important discovery could lead to new treatments for nerve damage caused by diabetes or traumatic injuries. Peripheral nerves connect the brain and spinal cord to the body, and without them, there is no movement or sensation. Peripheral nerve damage is common and often irreversible. This discovery is published in the July 7, 2010 edition of the Journal of Neuroscience.

12 Jul 2010

Biovest’s publicly-traded shares quoted on newly launched OTCQB Market

Biovest International, Inc., a biotechnology company advancing its personalized cancer vaccine targeting non-Hodgkin's lymphoma, today announced that the Company's publicly-traded shares are now being quoted on the newly launched OTCQB™ Market. The upgraded stock listing is a direct result of Biovest filing its Annual Reports (on Form 10-K) and its Quarterly Reports (on Form 10-Q) with the Securities and Exchange Commission (SEC), as the Company advances plans to emerge from reorganization.

12 Jul 2010

British Mycological Society announces 'The Biology of Fungi' programme at IMC9

The British Mycological Society, in association with Elsevier, the world-leading publisher of scientific, technical and medical information, today announced the final programme for the 9th Mycological Congress IMC9: The Biology of Fungi. This congress takes place every 4 years at a different venue around the world.

12 Jul 2010